Loading clinical trials...
Loading clinical trials...
A Randomized Investigator and Patient Blind Placebo-controlled Parallel Group First in Human and Proof of Concept Study to Evaluate the Safety Tolerability and Efficacy of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ
Conditions
Interventions
Cutaneous Cream application
Placebo Cutaneous Cream application
Locations
8
United States
Novartis Investigative Site
Phoenix, Arizona, United States
Novartis Investigative Site
Fountain Valley, California, United States
Novartis Investigative Site
Gainesville, Florida, United States
Novartis Investigative Site
Phillip, Australian Capital Territory, Australia
Novartis Investigative Site
Westmead, New South Wales, Australia
Novartis Investigative Site
Benowa, Queensland, Australia
Start Date
December 15, 2017
Primary Completion Date
November 1, 2018
Completion Date
November 1, 2018
Last Updated
December 11, 2020
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions